Somnomed Ltd
ASX:SOM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.195
0.52
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Somnomed Ltd
Revenue
Somnomed Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Somnomed Ltd
ASX:SOM
|
Revenue
AU$91.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
||
ImpediMed Ltd
ASX:IPD
|
Revenue
AU$10.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
11%
|
||
C
|
Cyclopharm Ltd
ASX:CYC
|
Revenue
AU$29m
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
Cochlear Ltd
ASX:COH
|
Revenue
AU$2.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
||
Optiscan Imaging Ltd
ASX:OIL
|
Revenue
AU$1.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
29%
|
||
EMvision Medical Devices Ltd
ASX:EMV
|
Revenue
AU$11.6m
|
CAGR 3-Years
182%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
Somnomed Ltd
Glance View
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.
See Also
What is Somnomed Ltd's Revenue?
Revenue
91.7m
AUD
Based on the financial report for Jun 30, 2024, Somnomed Ltd's Revenue amounts to 91.7m AUD.
What is Somnomed Ltd's Revenue growth rate?
Revenue CAGR 10Y
12%
Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for Somnomed Ltd have been 13% over the past three years , 9% over the past five years , and 12% over the past ten years .